How Ubigene Simplifies Genome-Wide CRISPR Screening for Functional Genomics Research

CRISPR-based pooled screening has become a cornerstone technology in functional genomics, enabling systematic interrogation of gene function, target identification, and mechanism-of-action studies at the genome scale. As the demand for high-quality screening data continues to grow in both academic and biopharmaceutical research, selecting a technically robust CRISPR screening provider is critical to ensuring experimental reproducibility, biological relevance, and downstream translational value.

Given the complexity of sgRNA library design, lentiviral delivery, screening execution, and bioinformatics analysis, researchers should evaluate service providers across several core dimensions, including sgRNA library quality, screening rigor, and NGS data analysis capabilities.

To address these challenges, CRISPR-based tools such as genome-wide knockout libraries, CRISPRi, and CRISPRa have become essential for functional genomics research.  In this article, we will explore how Ubigene simplifies genome-wide CRISPR screening through its CRISPR-iScreen™ platform, ready-to-use screening libraries, and integrated gene-editing solutions.

What Is Genome-Wide CRISPR Screening?

Genome-wide CRISPR screening is a high-throughput research approach used to analyze gene function across thousands of genes at the same time. It helps researchers identify genes linked to specific biological processes, disease pathways, and drug responses more efficiently.

Some important components of genome-wide CRISPR screening include:

• Genome-wide knockout librariesused to disable genes across the genome
• CRISPRi systemsdesigned to suppress gene expression
• CRISPRa systemsused to activate target genes
• CRISPR screening librariescontaining guide RNAs for large-scale studies
• Pooled library screening workflowsthat support high-throughput genomics studies and large-scale gene analysis

Genome-wide CRISPR screening is widely used in drug target discovery, cancer biology research, Functional Genomics Research, immunology research, therapeutic development, and gene function validation. Compared to traditional gene-editing methods, CRISPR screening enables researchers to study complex genetic interactions faster and on a much larger scale.

How Ubigene Supports Functional Genomics Research

Ubigene is a recognized provider of functional genomics and advanced CRISPR screening solutions. With expertise in Gene Editing, Cell Biology Technologies, and CRISPR Screening, Ubigene supports researchers through integrated platforms designed to simplify complex research workflows and large-scale screening studies.

Its integrated workflow functions as a one-stop CRISPR screening solution covering library construction, lentiviral packaging, pooled screening, sequencing, and bioinformatics analysis.

Ubigene Biosciences was co-founded by biological scientists from China, the United States, and France, and operates from a modern 3,000m² facility focused on advanced genome engineering and large-scale genomics applications.

Today, Ubigene supports researchers across more than 40 countries and has partnered with over 10,000 universities, biotechnology companies, and pharmaceutical organizations worldwide.

The company provides end-to-end gene-editing solutions backed by proprietary technology platforms and scientific expertise. Ubigene also maintains a large in-stock cell line resource with more than 13,000 cell lines available for multiple research applications.

With over 15 years of experience and more than 13,000 successful gene-editing projects completed, Ubigene has successfully modified 500+ cell lines, including tumor cell lines, immortalized cell lines, and induced pluripotent stem cells (iPSCs), with editing efficiencies of up to 97%.

Ubigene continues to provide high-quality, customized gene-edited cell models designed to support diverse basic research and large-scale CRISPR screening applications.

What Does Ubigene Actually Do?

Ubigene helps researchers and laboratories simplify complex gene-editing and genome-scale screening workflows through multiple specialized services and platforms.

Its work mainly focuses on four major areas:

• Gene Editing: Ubigene uses CRISPR/Cas9 technologies to modify, remove, activate, or suppress specific genes for research applications such as cancer biology, drug discovery, and functional genomics studies.
• CRISPR Screening Solutions: The company provides large-scale CRISPR screening libraries, lentiviral products, and CRISPR library cell poolsfor genome-wide knockout, CRISPRi, and CRISPRa research workflows.
• Plasmid and Vector Construction:Ubigene develops customized plasmids and lentiviral vectors that help researchers deliver target genes into cells for stable gene expression and genome engineering studies.
• Cell Line Development: Ubigene creates customized KO cell lines, knock-in models, point mutation models, and stable cell lines used in various biological and therapeutic research applications.

Through these integrated platforms, Ubigene supports researchers looking for scalable and efficient genome editing workflows.

What Makes Ubigene Stand Out in CRISPR Screening?

Ubigene provides end-to-end gene-editing services backed by proprietary technology platforms and scientific expertise, helping researchers simplify complex Functional Genomics Research workflows.

Some key advantages that make Ubigene stand out include:

• Large Ready-to-Use Inventory: Ubigene offers more than 40 CRISPR screening libraries, 150+ lentiviral products, and 600+ CRISPR library cell poolsdesigned for genome-wide knockout, CRISPRi, and CRISPRa applications across human and mouse models. This extensive inventory also helps reduce project turnaround times for many genome-wide CRISPR screening workflows.
• Advanced Gene-Editing Capabilities: Through its proprietary EZ-editor™platform, Ubigene supports precise genome engineering applications including KO cell lines, knock-in models, point mutations, overexpression systems, and gene knockdown models.
• High Screening Precision:Ubigene emphasizes rigorous screening quality standards using NGS-based validation The company highlights sgRNA coverage rates above 99% and low skew ratios (<10-fold) to improve screening consistency and reduce experimental bias.
• Optimized Experimental Workflows:The CRISPR-iScreen™ platform is designed to maintain optimized infection parameters, including MOI values below 0.3, helping ensure that individual cells receive a single sgRNA for accurate phenotype correlation during pooled screening studies.
• Support for Diverse Cell Models: The platform supports tumor cell lines, immortalized cell lines, and induced pluripotent stem cells (iPSCs) for various research applications.
• Integrated Functional Screening Services: Ubigene provides both in vitro and in vivo Functional screening servicesdesigned to support large-scale genome-wide CRISPR studies and drug target discovery research.
• Research-Focused Global Support: Ubigene continues to support more than 10,000 laboratories, pharmaceutical companies, and CROs worldwide through scalable gene-editing solutionsand CRISPR screening expertise.

Advanced Bioinformatics and Data Analysis

Large-scale CRISPR screening generates extensive sequencing datasets that require robust bioinformatics analysis for accurate interpretation.

To simplify this process, Ubigene developed the iScreenAnlys™ platform, which integrates standardized screening analysis pipelines with advanced algorithms such as MAGeCK, Drug-Z, MAGeCK-RRA, and MAGeCK-MLE.

The platform supports:

• sgRNA enrichment and depletion analysis
• Sequencing quality control validation
• Hit identification workflows
• Statistical analysis for pooled screening studies
• Pathway-level interpretation for downstream research

These integrated bioinformatics capabilities help researchers improve reproducibility and derive more actionable insights from genome-wide screening data.

Ubigene’s Core Services and Research Platforms

Ubigene offers multiple integrated platforms designed to simplify gene-editing services, CRISPR screening, and large-scale Functional Genomics Research workflows.

1. EZ-editor™ Gene Editing Cell Line Services

The EZ-editor™ platform supports customized genome engineering applications including gene knockout (KO), knock-in (KI), point mutation, and gene knockdown cell models. Ubigene also provides iPSC gene editing and customized cell line development for diverse research applications.

2. CRISPR-iScreen™ Screen

CRISPR-iScreen™ is Ubigene’s integrated screening platform designed for large-scale CRISPR screening libraries, including plasmid libraries, virus libraries, and CRISPR library cell pools. The platform supports both in vitro and in vivo screening as well as NGS sequencing workflows for functional genomics studies and drug target discovery.

3. EZ-OE™ Stable Cell Line

The EZ-OE™ platform focuses on stable overexpression and knockdown cell line generation. Ubigene highlights virus-free genome engineering workflows designed for stable and high-expression cell models used in long-term research studies.

4. Red Cotton OmniCell Bank

The Red Cotton OmniCell Bank provides access to more than 13,000 in-stock cell products, including KO cell lines, wild-type cell lines, Cas9 stable cell lines, luciferase cell lines, EGFP cell lines, and stem cell models for multiple research applications.

5. EZ-editor™ Series Products

Ubigene also offers EZ-editor™ Series Products, including genotyping kits, validation kits, culture media, and gRNA plasmid tools designed to support precise CRISPR applications and genome editing workflows.

6. Red Cotton CRISPR Gene Editing Designer

The Red Cotton CRISPR Gene Editing Designer is an automated platform developed by Ubigene for designing gene-editing strategies, gRNA workflows, primer design, and knockout validation support. The platform is built using large-scale gene-editing datasets and bioinformatics tools to simplify CRISPR project planning.

Research Publications Highlighting Ubigene Solutions

Ubigene has been cited in multiple peer-reviewed scientific publications across areas such as Functional Genomics Research, cancer biology, immunology, and genome engineering. Research teams worldwide have used Ubigene’s KO cell lines, lentiviral systems, and gene-editing services in high-impact studies published in leading scientific journals.

Some notable publications and journals include:

• Nature— Research involving deep whole-genome analysis of hepatocellular carcinomas utilized Ubigene-related knockout cell line services.
• Immunity— Studies exploring DNA sensing and polyamine metabolism cited Ubigene knockout cell models.
• Signal Transduction and Targeted Therapy— Researchers used Ubigene-related KO cell systems in influenza A virus and PANoptosis research.
• Journal of Hepatology— Functional studies involving metabolic liver disease research referenced Ubigene gene-editing services.

According to Ubigene’s 2024 research roundup, the company supported more than 115 scientific publications with a combined impact factor exceeding 1000 across multiple genome-editing applications.

This growing presence in peer-reviewed literature highlights how Ubigene continues to support scalable CRISPR screening, gene-editing workflows, and advanced functional genomics studies worldwide.

Conclusion

As genome-wide screening technologies continue to evolve, researchers increasingly need scalable and efficient CRISPR workflows that can support complex gene analysis studies.

Selecting a CRISPR screening partner is a strategic decision that impacts the trajectory of your research. By prioritizing technical metrics like uniformity, gRNA coverage, and proven academic citations, researchers can ensure that their functional genomics projects are built on a foundation of accuracy and global expertise.

From customized gene-editing services and KO cell line development to large-scale CRISPR screening libraries and functional screening platforms, Ubigene provides integrated solutions designed to simplify modern research applications.

With its ready-to-use inventory, proprietary CRISPR platforms, and global research support network, Ubigene continues to help laboratories improve screening efficiency and accelerate genome engineering studies.